Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma

Journal of Neuro-Oncology

Volumn 131, Issue 2, 2017, Pages 255-265

  Yang, Jian Kai ^a   Yang, Ji Peng ^a   Tong, Jing ^a   Jing, Shi Yuan ^a   Fan, Bo ^a   Wang, Feng ^a   Sun, Guo Zhu ^a   Jiao, Bao Hua ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

DNM3; Drug resistance; Exosome; Glioma; MiR 221; RELA

Indexed keywords

DYNAMIN III; MICRORNA 221; SHORT HAIRPIN RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR RELA; ALKYLATING AGENT; DACARBAZINE; MICRORNA; MIRN221 MICRORNA, HUMAN; RELA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CANCER RESISTANCE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DYNAMIN 3 GENE; EXOSOME; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GLIOMA; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL; VALIDATION PROCESS; ANALOGS AND DERIVATIVES; APOPTOSIS; BRAIN TUMOR; CELL SURVIVAL; DISEASE EXACERBATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DYNAMIN III; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; MICRORNAS; TRANSCRIPTION FACTOR RELA;

EID: 84994726562     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2308-5     Document Type: Article

References (23)

1. Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842–1850. doi:10.1001/jama.2013.280319
2. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123
3. Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis 1:97–117
4. Calin GA, Croce CM (2006) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66:7390–7394
5. Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C-G, Sabatino G, Negrini M, Maira G, Croce C, Farace M (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334:1351–1358
6. Azmi AS, Bao B, Sarkar FH (2013) Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 32:623–642
7. Yang C, Robbins PD (2011) The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011:842849
8. Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, Xu N, Xie Y (2014) Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PloS One 9:e109347
9. Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H (2014) Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res 6:391–401
10. Yau T, Wu C, Dong Y, Tang C, Ng S, Chan F, Sung J, Yu J (2014) MicroRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer 111:1765–1771
11. Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE (2014) Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate 74:1655–1662
12. Chen L, Zhang J, Han L, Zhang A, Zhang C, Zheng Y, Jiang T, Pu P, Jiang C, Kang C (2012) Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep 27:854–860. doi:10.3892/or.2011.1535
13. Zhang C-Z, Zhang J-X, Zhang A-L, Shi Z-D, Han L, Jia Z-F, Yang W-D, Wang G-X, Jiang T, You Y-P (2010) MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9:1
14. Hao J, Zhang C, Zhang A, Wang K, Jia Z, Wang G, Han L, Kang C, Pu P (2012) miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep 27:1504
15. Zhang Z, Chen C, Guo W, Zheng S, Sun Z, Geng X (2016) DNM3 attenuates hepatocellular carcinoma growth by activating P53. Med Sci Monit 22:197–205. doi:10.12659/msm.896545
16. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006
17. Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K, Nagata I, Yamashita S (2010) miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 296:241–248. doi:10.1016/j.canlet.2010.04.013
18. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18:282–289
19. Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, Tanino M, Kimura T, Nishihara H, Tanaka S (2012) STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther 11:1289–1299. doi:10.1158/1535-7163.MCT-11-0801
20. Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P, Wang G, Zhang A, Jia Z, Han L (2009) Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kipl in vitro and in vivo. Int J Oncol 34:1653
21. Orth JD, McNiven MA (2003) Dynamin at the actin–membrane interface. Curr Opin Cell Biol 15:31–39
22. Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, Fujii T, Nakayama G, Yamada S, Tanaka C, Kobayashi D, Kodera Y (2013) Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther 6:1417–1424. doi:10.2147/OTT.S51913
23. Hwang SK, Baker AR, Young MR, Colburn NH (2014) Tumor suppressor PDCD4 inhibits NF-kappaB-dependent transcription in human glioblastoma cells by direct interaction with p65. Carcinogenesis 35:1469–1480. doi:10.1093/carcin/bgu008